Curium Group, PeptiDream and PDRadiopharma Enroll First Patient to Registrational Clinical Trial of 64Cu-PSMA-I&T for Prostate Cancer in Japan
A Registrational Phase 2 clinical trial has been initiated for 64Cu-PSMA-I&T – a PET radiopharmaceutical targeting prostate-specific membrane antigen (PSMA) expressed on prostate cancer cells PARIS, Oct. 15, 2025 (GLOBE NEWSWIRE) — Curium Group announced toda
(Financial Post, 2025-10-15T06:33:20Z)